Endocrinology

 
Oral Semaglutide Lowers Risk of MACE 14% in High-Risk Adults: Final Phase 3 SOUL Trial Readout
March 31, 2025

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

CagriSema Achieves Significant Weight Loss in Phase 3 Trial: Daily Dose
March 31, 2025

Your daily dose of the clinical news you may have missed.

Omnipod 5 System Leads to Significant Glycemic Improvements After Direct Transition from MDI Insulin with CGM
March 27, 2025

Mean reduction in HbA1c was nearly 1% after transition from MDI plus CGM to Omnipod 5 in the first randomized trial to evaluate the shift in mode of insulin delivery.

Viking Therapeutics Completes Enrollment for Phase 2 Trial of Oral Obesity Tablet
March 26, 2025

Data from the phase 2 VENTURE-Oral Dosing Trial of VK2735 is expected in the second half of the year, the company said.

Investigational Keto Diet Pill Shows Promise in Phase 1 Trial: Daily Dose
March 21, 2025

Your daily dose of the clinical news you may have missed.

Massive Trump Administration Cuts to Federal Grants Halt National Diabetes Prevention Program
March 19, 2025

The 30-year program has tracked and compiled data on diabetes prevention, treatment, and outcomes, providing a foundation and insights for international research.

ZUPREME-1 Phase 2b Trial of Petrelentide for Obesity Completes Enrollment
March 19, 2025

The amylin analog at 5 doses will be compared with placebo when added to a reduced calorie diet and increased physical activity regimen for 42 weeks, said Zealand Pharma.

Osteoporosis Risk Screening Tools Fall Short in Younger Postmenopausal Women, New Research Reveals
March 18, 2025

Three of the 5 osteoporosis screening tools recommended by the USPSTF for identifying osteoporosis in postmenopausal women aged 50 yo 64 years proved suboptimal.

Bionic Pancreas for Type 1 Diabetes Found Feasible to Implement in Primary Care
March 14, 2025

The iLet bionic pancreas system conferred an average glucose of less than 183 mg/dL in 97% of adults with T1D in a small study.

CagriSema Phase 3 Update: Weight Loss of Nearly 16% Seen in REDEFINE 2 Trial
March 11, 2025

CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.